As research evolves, CAR-T therapy could transform the therapeutic landscape for MS, offering new hope for better disease management and outcomes. Dr. Gregory Wu is a neurologist and professor of pathology and immunology at Washington University in St. Louis. In his webinar, Dr. Wu speaks about the importance of CAR-T cells and how they are currently being used, as well as how they can be an asset in MS care. Dr. Wu's current research focuses on the interactions between the immune system and the nervous system. He shares his insights on CAR-T therapy as a potential emerging treatment for MS. Listen to our whole webinar on the latest research in CAR-T therapy for MS here -> https://lnkd.in/eQZyrqZA Thank you to our sponsors Bristol Myers Squibb and Kyverna for making this content possible.
Can Do MS’ Post
More Relevant Posts
-
Jeremy Tilstra, MD, PhD, and Rachael Gordon, MD, PhD, from the UPMC Division of Rheumatology and Clinical Immunology, as well as collaborators from the University of Pittsburgh School of Medicine Departments of Immunology and Pathology, published a paper titled “B cell-intrinsic Myd88 Regulates Disease Progression in Murine Lupus” that demonstrates that targeting Myd88 or its upstream activators may be a viable therapeutic option for systemic lupus erythematosus. Read more ➡️ https://lnkd.in/eVch9F8F
-
Twin study identifies early immunological and metabolic dysregulation of CD8+ T cells in multiple sclerosis Science Magazine Multiple sclerosis (MS) is an inflammatory neurological disease of the central nervous system with a subclinical phase preceding frank neuroinflammation. CD8+ T cells are abundant within MS lesions, but their potential role in disease pathology remains unclear. Using high-throughput single-cell RNA sequencing and single-cell T cell receptor analysis, we compared CD8+ T cell clones from the blood and cerebrospinal fluid (CSF) of monozygotic twin pairs in which the cotwin had either no or subclinical neuroinflammation (SCNI). We identified peripheral MS-associated immunological and metabolic alterations indicative of an enhanced migratory, proinflammatory, and activated CD8+ T cell phenotype, which was also evident in cotwins with SCNI and in an independent validation cohort of people with MS. Together, our in-depth single-cell analysis indicates a disease-driving proinflammatory role of infiltrating CD8+ T cells and identifies potential immunological and metabolic therapeutic targets in both prodromal and definitive stages of the disease. https://lnkd.in/eBnGnZHD
-
-
Dr. Owen Witte, presidential chair in developmental immunology at UCLA Health, details how the California Institute for Immunology and Immunotherapy (CIII) is slated to become an epicenter for innovation. Through streamlined collaboration, research at this site will usher a new future for patient treatment options.
-
Lab and Mouse Colony Manager | Joint PhD student KU Leuven/Edinburgh | Immunology | FACS | Imaging | Pre-clinical models
🚨 Paper allert! 🚨 I'm thrilled to share that our manuscript, "Intercellular interaction between FAP+ fibroblasts and CD150+ inflammatory monocytes mediates fibro-stenosis in Crohn’s disease", is now published in the Journal of Clinical Investigation! Read the full study here: https://lnkd.in/ervqE_nf 🔍 Highlights: Critical Interaction: Identified interaction between CD150+ inflammatory monocytes and FAP+ fibroblasts driving fibro-stenosis in Crohn’s disease. Key Regulator: TWIST1 transcription factor is crucial for fibroblast activation and ECM deposition. Therapeutic Potential: Targeting TWIST1 can inhibit fibroblast activation, reducing ECM production and collagen deposition, offering a promising approach to prevent fibro-stenosis. A huge thank you to all our collaborators for their incredible support and dedication! 🙌 #CrohnsDisease #Research #FibroStenosis #ClinicalInvestigation #HealthInnovation #Immunology #IBD Bo-Jun Ke, Saeed Abdurahiman, Gaia Zanella, Sneha Santhosh, Veronica De Simone, Anissa Zouzaf, Lies van Baarle, Michelle Stakenborg, Sare Verstockt, Gianluca Matteoli, Bram Verstockt, Severine Vermeire, Gabriele Dragoni
Intercellular interaction between FAP + fibroblasts and CD150 + inflammatory monocytes mediates fibro-stenosis in Crohn’s disease
jci.org
-
🌟 Exciting News! 🌟 I'm thrilled to share that my article, "Serum PIVKA-II Reference Interval of Healthy Population and Establishment of Its Cutoff Value for Hepatocellular Carcinoma Diagnosis in Pakistan," has received another citation! 🎉 As a researcher focused on hepatic diseases, tumor markers, and reference intervals, it’s incredibly rewarding to see how this work is contributing to the broader scientific conversation and potentially aiding in the early diagnosis of Hepatocellular Carcinoma (HCC). Research like this helps refine diagnostic criteria, leading to more accurate and timely treatments for liver cancer. Check out the article here: https://lnkd.in/ep7_WW5k I look forward to continuing this journey of exploration in liver disease and diagnostics! 💡 #ResearchImpact #Hepatology #TumorMarkers #HepatocellularCarcinoma #LiverCancer #ReferenceIntervals #MedicalResearch #PIVKAII #Citations #ScientificProgress #ClinicalChemistry #LaboratoryMedicine #Pathology #Biochemistry #Cirrhosis #EarlyDiagnosis
(PDF) Serum PIVKA-II: Reference Interval of Healthy Population and Establishment of Its Cutoff Value for Hepatocellular Carcinoma Diagnosis in Pakistan
researchgate.net
-
"Key insights in neuroimmunology and #MOGAD pathogenesis have been learned from #MOG experimental autoimmune encephalomyelitis (EAE), described 2 decades before the term MOGAD was introduced. MOG-specific T cells are required in MOG EAE, and while anti-MOG Abs can exacerbate EAE and CNS demyelination, those Abs are neither necessary nor sufficient to cause EAE. Knowledge regarding the spectrum of MOGAD #clinical and #radiologic presentations is advancing rapidly, yet our grasp of MOGAD pathogenesis is incomplete. Understanding both the humoral and cellular immunology of MOGAD has implications for diagnosis, treatment, and prognosis." https://lnkd.in/g4RQSJpy Carson E Moseley; Akash Virupakshaiah, MD; Scott S. Zamvil
-
-
Controlling inflammation helps in lifespan extension and aging The therapeutic drug rapamycin, which is normally used in cancer therapy and after organ transplants, can extend the lifespan and health span of laboratory animals. Understanding how rapamycin extend lifespan is important, as it helps to prevent unwanted side effects. "We know that rapamycin extends lifespan via two mechanisms: increased autophagy and decreased activity of a protein called S6K. It has been shown that mice with altered S6K live longer. But the mechanism by which S6K extends lifespan is unclear," says a co-author of the study. The researchers were able to show that an altered activity of S6K influences the endolysosomes. These break down material in the cells and play an important role in regulating various cellular processes, such as inflammatory reactions. The researchers also identified an important link between the endolysosomal system and age-related inflammation: the protein syntaxin 13. This protein is increased in the liver of rapamycin-treated mice, suggesting that the regulation of the endolysosomal system and the control of inflammatory pathways during ageing is similar between flies and mice. #ScienceMission #sciencenewshighlights https://lnkd.in/gGJV-VVa
-
-
Biomarker testing research is transforming how we understand and manage diseases in critical areas such as neurology, oncology, immunology, cardiology, and infectious disease. By identifying diseases earlier, researchers can improve patient outcomes and tailor treatment approaches. Join our upcoming webinar with Fierce Biotech to: ➡️ Discover solutions for meeting demanding clinical timelines ➡️ Explore cutting-edge biomarker technologies revolutionizing clinical trials ➡️ Gain insights into leveraging biomarkers for deeper disease understanding Register today: https://bit.ly/4de0paU #Biomarkers #ClinicalResearch #HealthcareInnovation
-
-
PhD student at CRUK MI, committed to continuous learning and professional development, with a genuine interest in Cancer research.
Curious about my research in Acute Myeloid Leukaemia? Watch my quick explainer video bellow!
✨ Day in the Life of a Leukaemia PhD researcher ✨ Florentia Mousoullou is a Non-Clinical PhD in the CRUK Manchester Institute Leukaemia Immunology & Transplantation group. 🧬👩🔬 In this video she tells us about her research into improving outcomes for patients with acute myeloid leukaemia (AML), takes us on a tour of the tissue culture labs in the Paterson Building and shares her experience of seeing clinical practice in action at the Christie Hospital.
-
Postdoc @University of North Carolina at Chapel-Hill I Immunology I Inflammatory disease I Drug Development I Biomarker I Preclinical study I Vaccine R&D.
This study underscores the significant role of immune activation in amyloid-targeting immunotherapy. The findings reveal that Aβ antibody engagement at cerebral amyloid angiopathy (CAA) sites induces perivascular macrophage activation and triggers vascular injury, including smooth muscle cell loss and blood-brain barrier breakdown. Through advanced techniques like RNA in situ hybridization and digital spatial profiling, the study identifies distinct immune responses and Trem2+ macrophage subsets involved in the vascular damage, highlighting the complex interplay between immune cells and CAA-related pathology. Further research is necessary to understand the molecular mechanisms underlying microhemorrhages associated with Aβ immunotherapy. https://lnkd.in/dFBkZmvM
